← Catalyst calendarOBIO biotech catalysts & pipeline
ORCHESTRA BIOMED HOLDINGS INC · Data as of 2026-09-08
Upcoming catalysts
Atrioventricular Interval Modulation Therapy ("AVIM Therapy") — Topline data
next year
We expect 2026 will be a landmark year for Orchestra BioMed, with target completion of enrollment in the BACKBEAT study and primary endpoint results data to follow thereafter, given that the primary efficacy and safety endpoints are measured at three months follow-up.
Source filingAtrioventricular Interval Modulation Therapy ("AVIM Therapy") — Conference presentation
Q2 2027
Assuming primary endpoints are met, we and Medtronic intend to submit primary endpoint data as a late-breaking clinical trial presentation at a major cardiovascular conference in the second quarter of 2027, followed by marketing application submissions to the FDA and global regulatory agencies.
Source filingExplore the free biotech catalyst calendar